Treatment of canine atopic dermatitis with intravenously administered autologous bone marrow

This entry is article 4 of 7 in the February 2015 issue

Atopic dermatitis (AD) also known as atopic eczema, affects approximately 10% of dogs worldwide and is likely the most prevalent canine skin diseases requiring medical intervention. Current treatment options for dogs afflicted with this condition include antihistamines, corticosteroids, cyclosporine A, oclacitinib, and allergen-specific immunotherapy (ASIT) administered subcutaneously or sublingually, as well as adjunctive treatments such as topical and systemic antimicrobial therapy. It is difficult to avoid allergens in many cases.. Certain issues may arise with treatment options due to possible unreliable,therapeutic methods that may have adverse reactions, or come with significant financial burden. There is a great need for finding a novel, safe, and effective treatment for the management of canine atopic dermatitis.

Multipotent mesenchymal stem cells (MSCs) have been extensively evaluated in human medicine for their clinical applications in the repair of damaged tissues and in the treatment of chronic, degenerative inflammatory diseases because of their diverse wound healing and anti-inflammatory properties.

Our primary goal is to investigate the effectiveness of autologous Bone Marrow MSCs (BM-MSCs) in easing the clinical signs associated with canine AD and the safety of BM-MSCs given that no prior safety study has been performed at our hospital. Our secondary goal is to investigate the feasibility of this protocol for future applications in larger scale randomized controlled double-blinded clinical trials.

For more information regarding this study, please visit:

Investigation of a novel diet for support of dogs undergoing chemotherapy for mast cell tumors or multicentric lymphoma

This entry is article 2 of 7 in the February 2015 issue

Cancer is one of the most common conditions seen in older dogs and it is becoming more common for owners to opt to treat their pets with chemotherapy. Dogs undergoing chemotherapy may suffer from side effects of treatment such as vomiting, diarrhea, and reduced appetite. There are currently no commercial diets that are designed specifically to help support dogs with cancer undergoing chemotherapy by reducing the gastrointestinal side effects of chemotherapy.

The purpose of the study is to determine whether a specially formulated diet may reduce gastrointestinal side effects associated with chemotherapy and improve the quality of life of dogs undergoing chemotherapy

For more information regarding this study please visit:

Anesthesia Team the “Unsung Heroes” for this Older Pet

This entry is article 2 of 4 in the January 2015 issue


Herman, a 16-1/2-year old dachshund, presented to Foster Hospital by his owner Susan Buttrick when he was not able to move his hind legs. While this situation had happened before, the most recent incident did not respond to medication that had previously been effective. Herman had a history of a heart murmur and in recent years, Susan was afraid to have him undergo the sedation required for even a teeth cleaning. “My biggest fear was that Herman wouldn’t make it through any surgery that might have been required,” recalls Susan. Continue reading